During the 17th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub spoke with Hervé Tilly, Centre Henri-Becquerel and University of Rouen, Rouen, FR. We asked, Is Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) effective and safe in elderly patients with diffuse large B-cell lymphoma (DLBCL)?
Polatuzumab vedotin in combination with R-CHP was granted FDA approval for patients with untreated DLBCL in April this year. Tilly discusses results from a subgroup analysis of the POLARIX trial (NCT03274492), reviewing efficacy and safety in elderly patients with DLBCL. He focuses on the primary endpoints and important adverse events.
Visit www.lymphomahub.com for more information on this topic.
7 сен 2024